Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese by 溝上 裕士 et al.
Effects of daily aspirin on cancer incidence
and mortality in the elderly Japanese
著者（英） Kenji Yokoyama, Naoki Ishizuka, Naomi Uemura,
Yuji MIZOKAMI, Hideyuki Hiraishi, Mitsuru
Murata, Shinichiro Uchiyama, Tamio Teramoto,
Kazuyuki Shimada, Tsutomu Yamazaki, Shinichi
Oikawa, Masahiro Sugawara, Katsuyuki Ando,
Yasuo Ikeda
journal or
publication title
Research and Practice in Thrombosis and
Haemostasis
volume 2
number 2
page range 274-281
year 2018-04
権利 (C) 2018 The Authors. Research and Practice in
Thrombosis and Haemostasis published by Wiley
Periodicals, Inc on behalf of International
Society on Thrombosis and Haemostasis.
This is an open access article under the terms
of the Creative Commons
Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any
medium, provided the original work is properly
cited, the use is non-commercial and no
modifications or adaptations are made.
URL http://hdl.handle.net/2241/00157623
doi: 10.1002/rth2.12097
Creative Commons : 表示 - 改変禁止
http://creativecommons.org/licenses/by-nd/3.0/deed.ja
274  |    Res Pract Thromb Haemost. 2018;2:274–281.wileyonlinelibrary.com/journal/rth2
 
Received: 29 November 2017  |  Accepted: 7 February 2018
DOI: 10.1002/rth2.12097
O R I G I N A L  A R T I C L E
Effects of daily aspirin on cancer incidence and mortality in the 
elderly Japanese
Kenji Yokoyama MD, PhD1  | Naoki Ishizuka PhD2 | Naomi Uemura MD, PhD3 |  
Yuji Mizokami MD, PhD4 | Hideyuki Hiraishi MD, PhD5 | Mitsuru Murata MD, PhD6 |  
Shinichiro Uchiyama MD, PhD7 | Tamio Teramoto MD, PhD8 | Kazuyuki Shimada  MD, PhD9 | 
Tsutomu Yamazaki MD, PhD10 | Shinichi Oikawa MD, PhD11 |  
Masahiro Sugawara MD, PhD12 | Katsuyuki Ando MD, PhD13 | Yasuo Ikeda MD, PhD14 |  
on behalf of the JPPP study group
1Department of Hematology/Oncology, Tokai University Hachioji Hospital, Hachioji, Japan
2Department of Clinical Trial Planning and Management, Clinical Research Center, Cancer Institute Hospital, Tokyo, Japan
3Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Ichikawa, Japan
4Endoscopic Center, University of Tsukuba Hospital, Tsukuba, Japan
5Department of Gastroenterology, Dokkyo Medical University, Mibu, Japan
6Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
7Clinical Research Center for Medicine, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno 
Medical Center, Narita, Japan
8Teikyo Academic Research Center, Teikyo University, Tokyo, Japan
9Department of Cardiology, Shin-Oyama City Hospital, Oyama, Japan
10Clinical Research Support Center, Center for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan
11Diabetes and Lifestyle-related Disease Center, Fukujuji Hospital, Kiyose, Japan
12Department of Internal Medicine, Japan Physician’s Association, Tokyo, Japan
13Department of Internal Medicine, Kitamura Memorial Clinic, Tokyo, Japan
14Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis 
and Haemostasis.
Part of this manuscript was presented at 57th American Society of Hematology Annual Meeting (Orlando, Florida, USA, December 5-8, 2015) as poster presentation, and 39th Japanese 
Society of Thrombosis and Hemostasis (Nagoya, Japan, June 8-10, 2017) as oral presentation.
Correspondence
Kenji Yokoyama, Department of 
Hematology/Oncology, Tokai University 
Hachioji Hospital, Hachioji, Japan.
Email: yk092750@tsc.u-tokai.ac.jp
Funding information 
This work was supported by the Waksman 
Foundation of Japan. The Japanese Primary 
Prevention Project (JPPP) was supported 
by the Japanese Ministry of Health, Labor, 
and Welfare (0805002) and the Waksman 
Foundation of Japan. Enteric-coated 100-
mg aspirin tablets were provided free of 
Abstract
Background: Long- term follow- up of studies to investigate preventive effects of as-
pirin on arterial thrombosis indicate that aspirin reduces the incidence and mortality 
of some cancers in Western populations.
Objectives: To explore the effects of aspirin on cancer incidence and mortality in the 
elderly Japanese.
Patients/Methods: Patients aged 60 to 85 years, presenting with hypertension, dyslipi-
demia, or diabetes mellitus (n = 14 601, 7297 in the aspirin group and 7304 in the 
 no- aspirin group) participated the Japanese Primary Prevention Project (JPPP), a 
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1  | INTRODUC TION
Aspirin is a widely used anti- platelet drug. Numerous studies have 
demonstrated the effects of aspirin on the secondary prevention 
of arterial thrombosis1 and several studies have investigated the 
effects of aspirin use for the primary prevention of atherosclerotic 
diseases.2–7 Long- term follow- up of these studies established that 
regular daily aspirin use reduces the incidence, distant metasta-
sis, and mortality of some cancers after approximately 5 years.8–11 
Several case- control studies and cohort studies also revealed simi-
lar long- term effects of aspirin.12–18 The evidence for the long- term 
inhibitory effects of aspirin on cancer incidence and cancer- related 
death is most prominent for gastrointestinal cancer, including col-
orectal cancer (CRC),19 and recently the US Preventive Services Task 
Force recommended initiating low- dose aspirin use for the primary 
prevention of cardiovascular disease and CRC in adults aged 50 to 
59 years who have a 10% or greater 10- year cardiovascular disease 
risk, are not at increased risk for bleeding, have a life expectancy 
of at least 10 years, and are willing to take low- dose aspirin for at 
least 10 years.20 However, cancer incidence and mortality increases 
with advancing age, and the incidence and mortality of cancer is 10 
times and 16 times greater in older adults, respectively, than in those 
younger than 65.21 Cancer is the leading cause of death in Japan, and 
according to the Japanese Cancer Institute registry data, 1 014 000 
patients were estimated to be newly diagnosed with cancer, and 
378 000 patients were estimated to die from cancer in 2017.22 
Approximately half of Japanese people suffer from cancer during 
their lifetime, and one- third die from cancer. Therefore, it is crucial 
to assess the effects of aspirin on cancer incidence and mortality in 
the elderly Japanese, and the current evidence is insufficient.
We previously reported the results of the Japanese Primary 
Prevention Project (JPPP), which examined the inhibitory effects of 
aspirin on vascular events in the elderly Japanese population (age 
60- 85 years, mean ± SD, 70.6 ± 6.2 years) with no previous history 
of arterial thrombosis.23 We performed a subanalysis of the JPPP to 
explore the effects of aspirin on cancer incidence and mortality in 
older Japanese by analyzing the in- trial cancer incidence and mortal-
ity of patients participating in the JPPP.
2  | METHODS
2.1 | Patients
The JPPP was a multicenter, open- label, randomized, parallel- 
group trial. Patients aged 60 to 85 years presenting with hyperten-
sion, dyslipidemia, or diabetes mellitus, and having no history of 
charge by Bayer Yakuhin. The Japanese 
Ministry of Health, Labor, and Welfare and 
the Waksman Foundation of Japan had no 
role in the design and conduct of the study; 
collection, management, analysis, and inter-
pretation of the data; preparation, review, 
or approval of the manuscript; and decision 
to submit the manuscript for publication.
multicenter, open- label, randomized, parallel- group trial. A subanalysis of JPPP was per-
formed to analyze the incidence of newly diagnosed cancer and death related to cancer.
Results: The cumulative incidence of newly diagnosed cancer was 5.60% (4.65- 
6.64%) in the aspirin group and 4.14% (3.67- 4.66%) in the no- aspirin group. The haz-
ard ratio for newly diagnosed cancer was 1.24 (1.06- 1.46), and the cancer incidence 
was significantly higher in the aspirin group. The cumulative cancer mortality was 
1.96% (1.65- 2.31%) in the aspirin group and 1.87% (1.56- 2.22%) in the no- aspirin 
group, with no statistically significant difference. The Fine and Gray model suggested 
that the difference in the incidence of newly diagnosed cancer between the two 
groups decreased year by year.
Conclusions: Low- dose aspirin use did not reduce the cancer incidence or cancer 
mortality during a 5- year- average study period in the elderly Japanese. The cancer 
incidence in the aspirin group might decrease, however, to less than that in the no- 
aspirin group after the study period. Aspirin use might have led to earlier cancer diag-
nosis in our study.
K E Y W O R D S
aspirin, cancer, elderly, incidence, Japanese
Essentials
• The effects of aspirin on cancer incidence and mortality in the elderly Japanese are not clear.
• We analyzed cancer incidence and mortality in the Japanese Primary Prevention Project (JPPP).
• Low-dose aspirin for 5 years did not reduce cancer incidence or cancer mortality in the JPPP.
• Cancers might be diagnosed earlier in the aspirin group.
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atherosclerotic disease, were recruited by primary care physicians 
at 1007 clinics in the 47 prefectures of Japan between March 2005 
and June 2007 (clinicaltrials.gov Identifier: NCT00225849). The 
study was approved by the institutional review board of each par-
ticipating center, and written informed consent was obtained from 
all participants. We randomized the patients to receive a 100- mg 
tablet of enteric- coated aspirin once daily or not, and followed 
them for up to 6.5 years with the last follow- up exam in May 2012. 
The primary outcome was a composite of death from cardiovascu-
lar causes (myocardial infarction, stroke, and other cardiovascular 
causes), nonfatal stroke (ischemic or hemorrhagic, including unde-
fined cerebrovascular events), and nonfatal myocardial infarction.23 
Secondary endpoints included cause- specific mortality. Collection 
of the detailed clinical information of the patients and annual reports 
of adverse events, including cancer, were mandatory for registered 
physicians. The diagnosis of cancer was assessed centrally and an-
nually by experts comprising a multidisciplinary event adjudication 
committee that was blinded to treatment based on the reports of 
adverse events. We analyzed the incidence and mortality of newly 
diagnosed cancer (ie, excluding recurrences of prerandomization 
cancers) in this population to evaluate the effect of aspirin on cancer 
in the elderly Japanese.
2.2 | Statistical analyses
The cumulative incidence rate was estimated by Gray’s non- 
parametric approach which treated deaths without cancer as com-
peting events.24 The difference between two groups was tested by 
Gray’s test, and hazard ratio (HR) was estimated by Fine and Gray 
model. The time dependency of proportional hazard assumption was 
also assessed by Fine and Grey model which included a log (time) 
term. SAS version 9.4 (SAS Institute, Cary, NJ, USA) was used for all 
statistical analyses. Statistical tests were two- sided with an alpha 
level of .05.
3  | RESULTS
3.1 | Patients
A total of 14 688 patients were randomized to the aspirin group 
(n = 7323) or the no- aspirin group (n = 7335). Of the 7323 patients 
randomized to the aspirin group, 26 were excluded, and of 7335 pa-
tients randomized to the no- aspirin group, 31 were excluded from 
the analysis because they never visited the registered physician after 
randomization. Finally, 7297 in the aspirin group and 7304 in the no- 
aspirin group were included in analysis (Figure 1). Both groups were 
well balanced in terms of the male- to- female ratio, age, underlying 
diseases (ie, hypertension, dyslipidemia, diabetes), body mass index, 
and current smoking habit (Table 1). The median follow- up period 
was similar in the aspirin and no- aspirin groups (5.01 years for the 
aspirin group and 5.02 years for the no- aspirin group).23
3.2 | Cancer incidence and mortality
Cancer was newly diagnosed in 332 (aspirin group) and 271 (no- 
aspirin group) patients.
The cumulative incidence of newly diagnosed cancer was 5.60% 
(4.65- 6.64%) in the aspirin group and 4.14% (3.67- 4.66%) in the no- 
aspirin group. In the aspirin group, the HR for newly diagnosed can-
cer was 1.24 (1.06- 1.46) compared to the no- aspirin group, and the 
incidence of newly diagnosed cancer was significantly higher than 
that in the no- aspirin group (P = .008) (Figure 2). CRC (66 [aspirin] 
and 50 [no- aspirin]) was most often diagnosed in the study popu-
lation, followed by gastric (55 [aspirin] and 49 [no- aspirin]) and lung 
(56 [aspirin] and 37 [no- aspirin]) cancer (Table 2). The number of indi-
vidual cancers was small, therefore we combined some cancers and 
divided into two categories: gastrointestinal (GI) cancer and non- GI 
cancer. GI cancer was newly diagnosed in 176 (aspirin group) and 
151 (no- aspirin group) patients, and the cumulative incidence of GI 
F IGURE  1 Flow of patients through the Japanese Primary Prevention Project (JPPP) subanalysis of the incidence and mortality of newly 
diagnosed cancer. 7323 patients and 7335 patients were randomized to the aspirin group and no- aspirin group, respectively. Of the 7323 
patients in the aspirin group, 26 were excluded from the analysis because they never visited the registered physician after randomization, 
and 7297 were included in analysis. Of the 7335 patients in the no- aspirin group, 31 were excluded from the analysis because they never 
visited the registered physician after randomization, and 7304 were included in analysis
14658 Randomized
7323 Patients randomized to receive 7335 Patients randomized to receive
no aspirin
31 Never visited
registered physician
enteric-coated aspirin (100 mg/day)
26 Never visited
registered physician
7297 Included in analysis of the incidence 7304 Included in analysis of the incidence
and mortality of newly diagnosed cancer and mortality of newly diagnosed cancer
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cancer was 2.62% (2.25- 3.03%) in the aspirin group and 2.31% (1.96- 
2.70%) in the no- aspirin group, respectively (Figure 3A). Non- GI can-
cer was newly diagnosed in 163 (aspirin group) and 123 (no- aspirin 
group), and the cumulative incidence of non- GI cancer was 3.12% 
(2.28- 4.15%) in the aspirin and 1.92% (1.59- 2.29%) in the no- aspirin 
group, respectively (Figure 3B). The HRs for GI cancer and non- GI 
cancer in the aspirin group compared to the no- aspirin group were 
1.18 (0.95- 1.46), and 1.34 (1.06- 1.69), respectively. No statistically 
significant difference in the HR for GI cancer was detected between 
the aspirin group and no- aspirin group (P = .138), while the incidence 
of non- GI cancer in the aspirin group was significantly higher than 
that in the no- aspirin group (P = .014).
Total death and death related to newly diagnosed cancer oc-
curred in 303 and 134 (aspirin group), and 308 and 125 (no- aspirin 
group), and the cumulative mortality related to newly diagnosed 
cancer was 1.96% (1.65- 2.31%) in the aspirin group and 1.87% (1.56- 
2.22%) in the no- aspirin group, respectively. In the aspirin group, 
the HR for cancer related death was 1.08 (0.85- 1.38) compared to 
the no- aspirin group, and the risk of cancer- related death did not 
differ significantly between the two groups (P = .527) (Figure 4). 
Furthermore, the Fine and Gray model suggested that the differ-
ence in the incidence of newly diagnosed cancer between the two 
groups decreased year by year (Figure 5). The number of deaths due 
to cancer after 5 years of follow- up was relatively small, but there 
was a trend toward fewer deaths in the aspirin group (5 [aspirin] vs 
16 [no–aspirin]; data not shown).
4  | DISCUSSION
In this subanalysis of the JPPP, the cumulative incidence of newly 
diagnosed cancer was significantly higher in the aspirin group 
(Figure 2). In contrast to other recent reports demonstrating inhibi-
tory effects of aspirin on cancer incidence and cancer- related mor-
tality, especially CRC,8–18 we unexpectedly found that the cancer 
incidence was significantly higher in the aspirin group than in the 
no- aspirin group and failed to show preventive effects of aspirin on 
cancer incidence or mortality during the average study period of 
5 years.
Factor Statistics Aspirin group No- aspirin group Total
Total N (%) 7297 (100) 7304 (100) 14 601 (100)
Sex
Men N (%) 3083 (42.3) 3096 (42.4) 6179 (42.3)
Women N (%) 4214 (57.7) 4208 (57.6) 8422 (57.7)
Age Mean (SD) 70.6 (6.2) 70.5 (6.2) 70.6 (6.2)
<70, N (%) 3263 (44.7) 3274 (44.8) 6537 (44.8)
≥70, N (%) 4034 (55.3) 4030 (55.2) 8064 (55.2)
HT N (%) 6197 (84.9) 6195 (84.8) 12 392 (84.9)
DL N (%) 5249 (71.9) 5245 (71.8) 10 494 (71.9)
DM N (%) 2469 (33.8) 2477 (33.9) 4946 (33.9)
HT & DL N (%) 4316 (59.1) 4302 (58.9) 8618 (59.0)
DL & DM N (%) 1808 (24.8) 1809 (24.8) 3617 (24.8)
HT & DM N (%) 1950 (26.7) 1953 (26.7) 3903 (26.7)
HT & DL & 
DM
N (%) 1456 (20.0) 1451 (19.9) 2907 (19.9)
BMI Mean (SD) 24.2 (3.5) 24.2 (3.4) 24.2 (3.4)
≥25, N (%) 2670 (36.6) 2628 (36.0) 5298 (36.3)
Current 
smoking
N (%) 967 (13.3) 948 (13.0) 1915 (13.1)
BMI, body mass index; DL, dyslipidemia; DM, diabetes; HT, hypertension.
TABLE  1 Patient characteristics
F IGURE  2 Cumulative incidence of cancer in the aspirin and 
the no- aspirin group. The P value was determined using the log- 
rank test. CI, confidence interval; HR, hazard ratio. CI indicates 
confidence interval
0.10 Randomized group Aspirin
No-Aspirin
Aspirin 7297 7058 6781 6566 6293 3624 173
7304 7120 6894 6660 6373 3726 184No-Aspirin
HR 1.24 (95%CI, 1.06–1.46); P = 0.008
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If aspirin had direct or indirect carcinogenic effects that caused 
an increased incidence of newly diagnosed cancer in the aspirin 
group in our study, the difference in the incidence of newly diag-
nosed cancer between the aspirin and no- aspirin groups would in-
crease year by year and should also be accompanied by an increase 
in cancer deaths. The Fine and Gray model in our study, however, 
suggested that the difference in the incidence of newly diagnosed 
cancer between the two groups decreased year by year, and the can-
cer incidence in the aspirin group might decrease to less than that 
in the no- aspirin group after the study period (Figure 5). The cumu-
lative incidence of cancer- related death did not differ significantly 
between the aspirin and no- aspirin groups during the study period 
(Figure 4). These findings suggest that cancer might not occur more 
frequently in the aspirin group, but rather that cancers were diag-
nosed earlier in the aspirin group. Indeed, there was a trend toward 
fewer cancer deaths after the 5- year follow- up, which is consistent 
with previous observations,9,11 although these observations are 
based on a small number of cases.
It is not clear why our subanalysis failed to show the preventive 
effects of aspirin on cancer incidence or mortality. Hemorrhagic 
complications are common adverse events of patients taking as-
pirin. As previously reported, serious extracranial hemorrhage re-
quiring transfusion or hospitalization occurred in 62 (aspirin) and 
34 (no- aspirin) patients, and gastrointestinal hemorrhage occurred 
in 103 (aspirin) and 31 (no- aspirin) patients in our study popula-
tion.23 Although the definition of hemorrhagic complications var-
ies among studies and available data are limited, the difference 
in the incidence of serious hemorrhagic complications between 
the aspirin group and no- aspirin group might be larger than that 
of other studies.10 The mean age of participants in the JPPP was 
70.6 years, whereas the mean age of participants in other trials 
was slightly >60 years.10 A recent report indicated that major 
bleeding increases steeply with age in patients receiving antiplate-
let drugs (mainly aspirin- based),25 and the difference in the mean 
age of participants might be related to the increased incidence of 
hemorrhagic complications in the aspirin group in our study. The 
increased incidence of hemorrhagic complications in the aspirin 
group might have encouraged physicians to perform thorough ex-
aminations to identify the causes, which could have resulted in an 
earlier diagnosis of cancer and an increased incidence of newly- 
diagnosed cancer. As shown in Figure 3A, the difference of the 
cumulative incidence rate of GI cancer between the aspirin and 
no- aspirin groups became larger in the first 3 years, then became 
smaller (Figure 3A). Such a trend was not found in non- GI cancer 
(Figure 3B). These findings might suggest that GI cancers were 
diagnosed earlier in the aspirin group. Although there was no ev-
idence of earlier diagnosis of cancers in the aspirin group in anal-
yses of previous trials,8,9,11 such a trend might be more apparent 
TABLE  2 Organ site of newly diagnosed any cancer
Aspirin No- Aspirin
Head and Neck 7 6
Lung 56 37
Breast 12 9
Esophageal 9 6
Gastric 55 49
Colon 66 50
Hepato, Biliary, Pancreatic 54 50
Urinary 16 13
Prostate 22 21
Uterus 8 5
Hematologic 26 23
Others 23 14
F IGURE  3 Cumulative incidence of gastrointestinal (GI) cancer (A) and non- GI cancer (B) in the aspirin and the no- aspirin group. The P 
value was determined using the log- rank test. CI, confidence interval; GI, gastrointestinal; HR, hazard ratio
0.10 Randomized group Aspirin
No-Aspirin
Aspirin 7297 7082 6817 6621 6367 3673 174
7304 7130 6920 6703 6424 3760 186
7297 7089 6842 6639 6372 3676 175
7304 7144 6928 6711 6436 3776 185No-Aspirin
HR 1.18 (95%CI, 0.95–1.46); P = 0.138 HR 1.34 (95%CI, 1.06–1.69); P = 0.014
Randomized group Aspirin
No-Aspirin
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with more recent advances in diagnosis and screening. The sen-
sitivity analysis which censors the participants after a report of 
hemorrhagic complications or gastrointestinal adverse events 
could exclude cancers that were found due to diagnostic proce-
dures to identify causes of these events. However, we did not have 
detail information about the day when the hemorrhagic complica-
tions or gastrointestinal adverse events occurred, and what diag-
nostic procedures were performed to detect the causes of these 
events, therefore we could not perform this analysis.
This study is a subanalysis of the JPPP, and the JPPP was termi-
nated prematurely because it was judged that the statistical power 
to detect a between- group difference in the primary endpoint would 
not be sufficient and continuing the study could put participants at 
risk for aspirin- related adverse events.23 Therefore, the median fol-
low- up period of our study was 5.02 years, shorter than those of 
most previous studies, and might not be long enough to evaluate 
the inhibitory effects of aspirin on cancer. The effects of regular as-
pirin use for 5 years or less on cancer incidence or mortality have 
been evaluated in several studies with inconsistent results. Rothwell 
et al. reported a meta- analysis of individual patient data from ran-
domized trials of daily aspirin vs no aspirin in the prevention of vas-
cular events, and revealed that aspirin reduced cancer incidence 
and deaths particularly after 5 years, with a weak effect on cancer 
incidence after 3 years,11 but they found no benefit of aspirin on 
cancer death before 5 years, and aspirin use for 5 years or longer 
reduced the risk of proximal colon cancer and rectal cancer in other 
studies.9,10 The Physicians’ Health Study3 and The Women’s Health 
Study26 were randomized trials that included cancer outcomes as 
predefined endpoints to evaluate the effects of aspirin on cancer 
incidence and mortality. The Physicians’ Health Study reported no 
association between aspirin use and CRC incidence over a 12- year 
follow- up period.27 The findings of the Women’s Health Study also 
did not support inhibitory effects of aspirin on CRC incidence over 
the originally planned 10- year follow- up period,26 but a reduced 
CRC incidence in the aspirin group was demonstrated over extended 
follow- up periods.28 These studies also did not show significant ef-
fects of aspirin use of 5 years or less on cancer. The dose of aspirin 
differed among these studies. The dose of daily aspirin ranged from 
81 to 500 mg in the studies analyzed by Rothwell.11 Every other day, 
325 mg and 100 mg of aspirin was administered in The Physicians’ 
Health Study3 and The Women’s Health Study,26 respectively. In our 
study, 100 mg of aspirin was administered daily. The difference of 
dose and schedule of aspirin might affect the short- term effects of 
aspirin on cancer in these trials, but further studies are needed to 
reach a conclusion.
Our study has some limitations. The JPPP was planned to eval-
uate the primary preventive effects of aspirin on the occurrence of 
cardiovascular diseases and death related to cardiovascular diseases. 
Although this was a relatively large- scale study and the aspirin and no- 
aspirin groups were well balanced, the study population, sample size, 
and study period were determined to evaluate the inhibitory effects 
of aspirin on cardiovascular diseases, and therefore these factors were 
not necessarily adequate to evaluate the effects of aspirin on cancer 
incidence and cancer mortality. The sample size in particular might not 
have been large enough to examine the effect of aspirin on specific 
types of cancer, and the study period might not have been long enough 
to confirm the effects of aspirin on cancer. As previously reported, a 
total of 89% of patients in the aspirin group continued taking the aspi-
rin at year 1 and 76% at year 5. In the no- aspirin group, the proportion 
of patients who began to take daily low- dose aspirin was 1.5% at year 
1 and 9.8% at year 5.23 The number of patients who did not adhere 
to the aspirin treatment regimen could affect the results of our study, 
but adherence rates were nevertheless still higher than those reported 
in similar trials of daily aspirin that did not employ run- in periods.8–11 
The number of patients lost to follow- up could also affect the results: 
791 in the aspirin group and 753 in the no- aspirin group were lost to 
follow- up during the study period.23 In addition, most registered phy-
sicians of the JPPP were primary care physicians who worked at their 
own clinics, and therefore cancers were often diagnosed at other hos-
pitals. These factors could lead to an underestimation of the frequency 
of cancer. A study with predefined regular examinations to detect 
cancer, for example, annual radiologic studies and endoscopic studies, 
F IGURE  4 Cumulative incidence of cancer related death in the 
aspirin and the no- aspirin group. The P value was determined using 
the log- rank test. CI, confidence interval; HR, hazard ratio
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might be needed to confirm the effects of aspirin on cancer incidence 
and mortality in an elderly population. Nevertheless, the JPPP trial is 
the largest completed randomized trial of daily aspirin vs control with 
follow- up to an average of 5 years in an elderly population, and there-
fore adds substantially to the previously reported data on cancer out-
comes from similar trials.
5  | CONCLUSION
Low- dose aspirin for 5 years did not reduce the cancer incidence 
or cancer mortality in the elderly Japanese patients during a 
5- year- average study period, but the Fine and Gray model suggested 
that the cancer incidence in the aspirin group might decrease to less 
than that in the no- aspirin group after the study period. Cancers 
might have been diagnosed earlier in the aspirin group in our study.
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